A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia

A. Filla, G. De Michele, G. Orefice, F. Santorelli, L. Trombetta, S. Banfi, F. Squitieri, G. Napolitano, D. Puma, G. Campanella

Research output: Contribution to journalArticlepeer-review


We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.

Original languageEnglish
Pages (from-to)52-55
Number of pages4
JournalCanadian Journal of Neurological Sciences
Issue number1
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia'. Together they form a unique fingerprint.

Cite this